Madrigal Pharmac SEC Filings

Madrigal Pharmaceuticals (MDGL) reported a Form 144 notice for the proposed sale of 4,100 shares of common stock through Morgan Stanley Smith Barney LLC on 08/15/2025. The filing lists an aggregate market value of $1,503,481.48 based on the transaction and shows 22,289,014 shares outstanding for the issuer. The shares were acquired and are being sold on the same date by exercise of options under a registered plan and payment was made in cash. The filer reports nothing to report for securities sold during the past three months and includes the standard attestation that the seller is not aware of undisclosed material adverse information.

Madrigal Pharmaceuticals (MDGL) filed a Form 144 reporting a proposed sale of 10,000 common shares through Morgan Stanley Smith Barney on 08/15/2025 on NASDAQ with an aggregate market value of $3,652,008.00. The filer states the shares were acquired the same day by exercise of options under a registered plan and paid in cash. The filing reports 22,289,014 shares outstanding, and shows no securities sold by the filer in the past three months. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.

Janus Henderson Group plc reports beneficial ownership of 2,191,753 shares of Madrigal Pharmaceuticals common stock, representing 9.9% of the class. The filing breaks this down by reporting persons and subsidiaries: JHIUS may be deemed the beneficial owner of 2,173,828 shares (9.8%), and the reporting tables show shared voting and shared dispositive power over 2,191,753 shares with no sole voting or dispositive power.

The filer certifies these holdings were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing also includes a power of attorney authorizing named compliance officers to execute required ownership reports on the company’s behalf.

Paul A. Friedman, a director of Madrigal Pharmaceuticals (MDGL), exercised a stock option for 129,172 shares at an exercise price of $9.45 and on 08/13/2025 sold those shares pursuant to a Rule 10b5-1 trading plan adopted March 14, 2025. The sales were executed in multiple transactions at weighted-average prices reported in tranches with ranges from $357.70 to $374.60. As a result of these transactions, Mr. Friedmans reported direct beneficial ownership declined from 316,336 shares to 187,164 shares. He also reports indirect ownership of 655,540 shares through SQN LLC (with the customary disclaimer regarding beneficial ownership). The option shares are reported as fully vested and exercisable.

Paul A. Friedman, a director of Madrigal Pharmaceuticals (MDGL), reported option exercises on 08/11/2025 and 08/12/2025 to acquire 3,203 and 43,605 shares, respectively, at an exercise price of $9.45 per share, and contemporaneous sales of those shares under a Rule 10b5-1 trading plan adopted March 14, 2025.

The sales were executed at weighted average prices ranging approximately from $350.00 to $359.87 per share, for a total of 46,808 shares sold. Following the reported transactions the reporting person’s direct beneficial ownership is 187,164 shares and he disclaims beneficial ownership of 655,540 shares held indirectly by SQN LLC (of which he and his spouse are managing members). The underlying options were fully vested and exercisable. The form was signed by attorney-in-fact Mardi Dier on 08/13/2025.

Rebecca Taub, a director of Madrigal Pharmaceuticals, reported stock option exercises and subsequent sales on August 11 and August 12, 2025. The filing shows she exercised options to acquire 3,200 shares on 08/11/2025 and 43,263 shares on 08/12/2025 at an exercise price of $9.45 per share, and then sold those shares under a Rule 10b5-1 trading plan adopted March 14, 2025.

The report lists total shares sold of 46,463 and weighted-average sale prices reported in the footnotes ranging between $350.00 and $359.78. Following these reported transactions the filing shows Ms. Taub with 461,044 shares directly beneficially owned and an indirect interest of 655,540 shares held by SQN LLC, of which she and her spouse are managing members.

Madrigal Pharmaceuticals (MDGL) filed a Form 144 reporting a proposed sale of 129,172 shares of Common stock to be effected through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $46,372,748. The shares were acquired by the filer through the exercise of stock options on 08/13/2025 and payment was in cash.

The filing also lists multiple recent Rule 10b5-1 sales by two insiders, Rebecca Taub and Paul A. Friedman, showing combined sales of 153,648 shares in the past three months that generated approximately $54,457,408 in gross proceeds. The form includes the standard representation that the seller does not possess undisclosed material adverse information.

Madrigal Pharmaceuticals (MDGL) filed a Form 144 reporting a proposed sale of 43,263 common shares through Morgan Stanley Smith Barney, with an aggregate market value of $15,120,418.50 and 22,289,014 shares outstanding. The filing states the shares were acquired and are to be sold on 08/12/2025 following an exercise of stock options, with payment in cash. The notice also lists multiple recent 10b5-1 insider sales by Rebecca Taub and Paul A. Friedman in July–August 2025, including large transactions on 07/16/2025. Several identifying fields for the filer/issuer in the provided form appear blank.

Madrigal Pharmaceuticals (MDGL) filed a Form 144 reporting a proposed sale of 43,605 shares of common stock through Morgan Stanley Smith Barney LLC with an aggregate market value of $15,239,947.50 and 22,289,014 shares outstanding. The filing states the shares were acquired by exercise of stock options on 08/12/2025 and paid in cash, with an approximate sale date of 08/12/2025. The form also lists multiple recent 10b5-1 sales by insiders Rebecca Taub and Paul A. Friedman in July–August 2025 that generated substantial gross proceeds, and the filing includes the standard representation that the seller is not aware of undisclosed material adverse information.